Vaishampayan, U. N., Elliott, T., Omlin, A. G., Graff, J. N., Hoimes, C. J., Tagawa, S. T., … Antonarakis, E. S. (2020). 227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199. In Annals of Oncology (Vol. 31, pp. S1330–S1330). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.10.447

Vaishampayan, U. N., T. Elliott, A. G. Omlin, J. N. Graff, C. J. Hoimes, S. T. Tagawa, C. Hwang, et al. “227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199.” In Annals of Oncology, 31:S1330–S1330. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.10.447.

Vaishampayan UN, Elliott T, Omlin AG, Graff JN, Hoimes CJ, Tagawa ST, et al. 227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199. In: Annals of Oncology. Elsevier BV; 2020. p. S1330–S1330.

Vaishampayan, U. N., et al. “227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S1330–S1330. Crossref, doi:10.1016/j.annonc.2020.10.447.

Vaishampayan UN, Elliott T, Omlin AG, Graff JN, Hoimes CJ, Tagawa ST, Hwang C, Kilari D, Tije AJT, McDermott RS, Gerritsen WR, Wu H, Kim J, Schloss C, de Bono JS, Antonarakis ES. 227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199. Annals of Oncology. Elsevier BV; 2020. p. S1330–S1330.